Shrestha et al. combined crizotinib with selumetinib, a MEK inhibitor, to investigate the effects on crizotinib-resistant ALK-positive lung cancer cells and found that the combination therapy could reduce the survival of tumor cells more evidently than single therapies [231]. Here, MAP2K7 is linked to lung cancer.